emerging GEP-NET drugs
Apr 26, 2024
Novartis’ LUTATHERA for GEP-NET Treatment: Ray of Hope for Pediatric Patients
2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects. On April 23, 2024, the FDA approved LUTATHERA (lutetium Lu 177 dotatate) for the treatment of pediatric patients aged 12 years and older with somatostatin receptor (SSTR)-positive gastro-...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
